Abivax SA
ABVX117.670USD
+6.960+6.29%
收盤 02/06, 16:00（美東）報價延遲15分鐘
0.00總市值
--本益比TTM
關於 Abivax SA 公司
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA簡介
公司代碼ABVX
公司名稱Abivax SA
上市日期Jun 26, 2015
CEOde Garidel (Marc)
員工數量- -
證券類型Depository Receipt
年結日- -
公司地址7-11 Boulevard Haussmann
城市PARIS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家France
郵編75009
電話33153830963
網址https://www.abivax.com/
公司代碼ABVX
上市日期Jun 26, 2015
CEOde Garidel (Marc)
Abivax SA公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mr. Marc de Garidel
Mr. Marc de Garidel
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Dr. June H. Lee, M.D.
Dr. June H. Lee, M.D.
Independent Director
Independent Director
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 1月19日 週一
更新時間: 1月19日 週一
持股股東
股東類型
持股股東
持股股東
佔比
TCG Crossover Management, LLC
9.67%
UBS Financial Services, Inc.
6.01%
Darwin Global Management Ltd
4.30%
Point72 Asset Management, L.P.
3.98%
Cormorant Asset Management, LP
2.65%
其他
73.39%
持股股東
持股股東
佔比
TCG Crossover Management, LLC
9.67%
UBS Financial Services, Inc.
6.01%
Darwin Global Management Ltd
4.30%
Point72 Asset Management, L.P.
3.98%
Cormorant Asset Management, LP
2.65%
其他
73.39%
股東類型
持股股東
佔比
Hedge Fund
33.85%
Investment Advisor
23.62%
Investment Advisor/Hedge Fund
8.93%
Research Firm
2.98%
Venture Capital
2.18%
Private Equity
1.77%
Pension Fund
1.00%
Bank and Trust
0.02%
其他
25.66%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
260
54.72M
74.37%
+10.98M
2025Q3
210
53.54M
52.22%
+19.70M
2025Q2
81
30.74M
57.27%
-1.09M
2025Q1
75
31.82M
50.24%
-38.10K
2024Q4
68
29.91M
44.59%
+2.48M
2024Q3
54
27.43M
45.93%
-700.83K
2024Q2
51
33.52M
46.25%
-227.21K
2024Q1
46
28.78M
34.33%
+7.18M
2023Q4
33
27.04M
1.75%
+20.54M
2023Q3
1
5.40M
0.00%
--
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
TCG Crossover Management, LLC
7.11M
9.67%
+1.05M
+17.42%
Sep 30, 2025
UBS Financial Services, Inc.
4.46M
6.06%
+4.29M
+2560.74%
Sep 30, 2025
Darwin Global Management Ltd
3.16M
4.3%
+3.16M
--
Sep 30, 2025
Point72 Asset Management, L.P.
2.93M
3.98%
+2.76M
+1642.45%
Sep 30, 2025
Cormorant Asset Management, LP
1.95M
2.65%
-180.00K
-8.45%
Sep 30, 2025
Paradigm BioCapital Advisors LP
1.56M
2.13%
+1.56M
--
Sep 30, 2025
Caligan Partners, LP
1.45M
1.97%
-222.48K
-13.29%
Sep 30, 2025
Fidelity Management & Research Company LLC
1.43M
1.94%
+417.90K
+41.26%
Sep 30, 2025
Fred Alger Management, LLC
1.23M
1.67%
+40.31K
+3.38%
Dec 31, 2025
Adar1 Capital Management LLC
1.35M
1.84%
-1.72M
-56.02%
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Simplify Health Care ETF
2.86%
Harbor Health Care ETF
0.7%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
0%
Simplify Health Care ETF
佔比2.86%
Harbor Health Care ETF
佔比0.7%
Fidelity Nasdaq Composite Index ETF
佔比0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
佔比0%
Innovator IBD Breakout Opportunities ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
